Appears On
Episode Appearances
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
“Replaced Emma Walmsley at GSK; first CEO role; will benefit from elevated compensation structure”
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program
View Analysis